Tilray Inc. ($TLRY) Stock Forecast: Down 6.6% Today

What is Tilray Inc.?

Tilray Brands Inc. (TLRY) is a company in the cannabis industry focusing on medical-grade cannabis products and entering the craft beer market. The stock faced a significant bearish movement in the recent trading session amid broader market declines.

Why is Tilray Inc. going down?

TLRY stock is down 6.6% on Jun 11, 2026 14:22

• Profit-taking by investors following a two-day winning streak caused a 2.90% drop in Tilray's stock price.
• Despite strategic initiatives such as launching the premium medical cannabis brand ARX in Germany and expanding US craft beer brands through BrewDog in the UK, market sentiment may have been affected by general market conditions.
• The overall decline in both the NASDAQ Composite and Dow Jones Industrial Average likely exacerbated pressure on Tilray's stock, leading to its underperformance.
• Investor caution may stem from the company's moderate GF Score™ of 60/100 and recent insider selling. However, the potential undervaluation highlighted by the price-to-sales ratio could present a buying opportunity for certain traders.

TLRY Price Chart

TLRY Technical Analysis

TLRY News

Tilray lines up US beer push through BrewDog bars in UK

Tilray is leveraging its recently acquired BrewDog UK bars to launch nine US beer brands in the UK, starting with 24 brews from various craft brewers. This initiative marks the initial phase of a broader strategy to expand Tilray's American craft beer portfolio across different retail and on-trade channels in the UK and Europe. Tilray views BrewDog's on-premise locations as a crucial "gateway" for this international expansion.

https://drinks-intel.com/beer/tilray-lines-up-us-beer-push-through-brewdog-bars-in-uk/

Tilray Brands Inc. stock falls Wednesday, underperforms market

Tilray Brands Inc. (TLRY) stock dropped 2.90% to $5.02 on Wednesday, facing a tough trading session that saw the NASDAQ Composite and Dow Jones Industrial Average also decline. This fall ended a two-day winning streak for Tilray.

https://www.marketwatch.com/data-news/tilray-brands-inc-stock-falls-wednesday-underperforms-market-fae4d59e-d39fbc2562b5?mod=mw_quote_news

Tilray brings US craft beer brands to UK through BrewDog

Tilray Brands is launching 24 SKUs from nine of its US craft beer labels in the UK through BrewDog’s bars and website, marking the first step in a broader strategy to distribute Tilray beer brands across the UK and continental Europe. This initiative follows Tilray's acquisition of some of BrewDog's assets and aims to eventually expand into UK grocery and on-trade, with potential future production at BrewDog's Scottish brewery. Tilray's president of International division, Rajnish Ohri, emphasized this as a significant milestone in their global beverage strategy, hinting at further expansion into various beverage categories.

https://www.just-drinks.com/news/tilray-brings-us-craft-beer-brands-to-uk-through-brewdog/

This US Cannabis Giant Is Launching Its First Premium Offering In Germany – Why It Matters?

Tilray Brands is launching its first premium medical-grade cannabis brand, ARX, in Germany. This strategic move aims to capitalize on Germany's growing medical cannabis market and increase Tilray's profits in high-margin products. The launch coincides with increasing optimism around cannabis regulation in the US, potentially benefiting cannabis stocks.

https://stocktwits.com/news-articles/markets/equity/this-us-cannabis-giant-is-launching-its-first-premium-offering-in-germany-why-it-matters/cZ06SwkR7TZ

Tilray (TLRY) Launches Premium Medical Cannabis Brand ARX in Ger

Tilray Brands Inc (TLRY) has launched ARX, a premium medical cannabis brand, in Germany, following two years of research and development. The new product line will be showcased at Mary Jane Berlin 2026. Despite a moderate GF Score™ of 60/100 and recent insider selling, Tilray's price-to-sales ratio suggests potential undervaluation in the market.

https://www.gurufocus.com/news/8909531/tilray-tlry-launches-premium-medical-cannabis-brand-arx-in-germany

Trending Today

Align Technology Inc. ($ALGN) Stock Forecast: Up 5.2% Today

Grab Holdings Limited ($GRAB) Stock Forecast: Up 7.1% Today

Electronic Arts Inc. ($EA) Stock Forecast: Down 0.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Up 5.0% Today

Advanced Micro Devices Inc. ($AMD) Stock Forecast: Up 5.1% Today

Reddit Inc ($RDDT) Stock Forecast: Up 5.0% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.6% Today

Stitch Fix Inc. ($SFIX) Stock Forecast: Up 5.2% Today

Corsair Gaming Inc. ($CRSR) Stock Forecast: Up 5.6% Today

Dollar Tree Inc. ($DLTR) Stock Forecast: Up 5.3% Today

Tilray Inc. Price History

11.05.2026 - TLRY Stock was down 6.6%

• Profit-taking by investors following a two-day winning streak caused a 2.90% drop in Tilray's stock price.
• Despite strategic initiatives such as launching the premium medical cannabis brand ARX in Germany and expanding US craft beer brands through BrewDog in the UK, market sentiment may have been affected by general market conditions.
• The overall decline in both the NASDAQ Composite and Dow Jones Industrial Average likely exacerbated pressure on Tilray's stock, leading to its underperformance.
• Investor caution may stem from the company's moderate GF Score™ of 60/100 and recent insider selling. However, the potential undervaluation highlighted by the price-to-sales ratio could present a buying opportunity for certain traders.

27.03.2026 - TLRY Stock was down 5.3%

• Investors opted to take profits today amidst Tilray's stock decline, following a period of volatility and speculation.
• Concerns arose among investors due to a director's sale of over 33,000 company shares, potentially impacting outlook and causing fears of dilution.
• Although positive developments such as U.S. cannabis rescheduling and the company's expansion plans emerged, the stock's decline suggests some skepticism among investors regarding the recent surge.
• Tilray's larger-than-expected quarterly loss and negative net margins may have also influenced the stock's downturn, prompting an evaluation of the company's financial standing in light of sector trends.

29.03.2026 - TLRY Stock was down 6.3%

• The stock price of Tilray dropped by 4.8% to $6.56, nearing its 52-week low and trading below its 200-day moving average, signaling bearish sentiment among investors.
• Despite the launch of new products by its subsidiary Manitoba Harvest, Tilray's stock faced continued selling pressure and technical indicators suggest a downside risk, potentially due to the company missing EPS estimates in the last quarter and reporting negative net margins.
• The underperformance of Tilray's stock compared to the broader market indices like the NASDAQ Composite and Dow Jones Industrial Average indicates specific challenges faced by the company, potentially related to its financial performance and market positioning.
• The overall US cannabis market is projected to grow significantly in the coming years, providing a positive industry outlook, but Tilray's specific stock movement today may be influenced by internal factors such as financial results and market sentiment rather than broader industry trends.

08.04.2026 - TLRY Stock was down 5.1%

• TLRY's stock decline aligns with the negative trading day across the market, with the NASDAQ Composite Index and the Dow Jones Industrial Average also experiencing losses.
• The launch of Widmer Brothers' "Stay Sunny" campaign and their new beer releases may have steered investor focus and funds away from Tilray, impacting its stock performance.
• CEO Irwin Simon's positive outlook on expanding medical cannabis operations in the U.S. may not have fully offset concerns about Tilray's revenue inconsistency and ongoing losses.
• Investor uncertainties regarding the sluggish federal cannabis legalization progress and heightened competition from established beverage companies could have added to the bearish sentiment surrounding Tilray Brands Inc.

28.03.2026 - TLRY Stock was down 5.3%

• The exclusive launch of Manitoba Harvest's Superfood Smoothie Boosters at Sprouts Farmers Market suggests potential competition in the health and wellness sector, impacting investor sentiment towards Tilray.
• Concerns about growing competition and market saturation in the US cannabis market may have prompted a sell-off of TLRY shares.
• Anticipation surrounding Tilray's upcoming Q3 earnings report, which showed a wider loss than expected but beat revenue estimates, created uncertainty among investors despite the company's market outperformance.
• The market's mixed reactions to Tilray's Q3 earnings, with the stock price dropping despite surpassing revenue expectations, may have led investors to reassess the company's financial standing and future outlook.

05.05.2026 - TLRY Stock was down 0.1%

• Despite varied market performance with the Dow Jones up and the NASDAQ down, Tilray's stock trended bearishly.
• The reacquisition of Atwater Brewery from Tilray Brands by a Detroit entrepreneur could be influencing Tilray's strategic focus and potentially affecting investor confidence.
• The launch of Breckenridge Rye Whiskey by Breckenridge Distillery, a Tilray Brands subsidiary, demonstrates the company's expansion efforts in the beverage industry amid stiff competition.
• Investors may be responding to the sale of Atwater Brewery by Tilray, hinting at potential shifts in the company's direction and contributing to the stock's bearish movement.

03.05.2026 - TLRY Stock was down 5.2%

• TLRY stock performed notably weaker than the broader market, declining sharply amidst industry fluctuations and expectations of potential changes in U.S. cannabis classification.
• Participation in discussions about cannabis regulations in Europe did not yield positive effects on the stock's trajectory.
• Various negative factors, including financial struggles, a high level of short selling, and reliance on U.S. federal policy shifts, influenced the bearish trend in TLRY stock.
• Despite recognition as a prominent player in the CBD market, TLRY's stock experienced a drop, breaking a recent streak of gains, which signaled investor hesitancy and a likelihood of profit-taking.

24.03.2026 - TLRY Stock was down 12.9%

• The stock price of Tilray Brands plummeted by 11.8% following insider selling of over 33,000 shares by a director, leading to increased trading volume and negative investor sentiment.
• Despite optimism in the cannabis sector due to potential reclassification of cannabis to Schedule III, concerns about potential dilution, wider-than-expected quarterly losses, and negative net margins contributed to the bearish movement.
• While there was speculation and anticipation surrounding the Trump administration's possible rescheduling of cannabis, the lack of official confirmation led to uncertainty and a sell-off in Tilray's stock.
• Tilray's readiness to expand into the U.S. medical cannabis market post-rescheduling highlights the company's strategic positioning, but until concrete regulatory changes are announced, the stock may continue to face volatility and downward pressure.

04.04.2026 - TLRY Stock was down 5.0%

• The stock's downward trend today could be linked to Tilray's larger-than-expected EPS loss, causing investor concerns over its financial standing.
• Despite positive remarks from the CEO regarding potential benefits from US cannabis reclassification, the market reaction may stem from Tilray's current lack of cannabis sales in the US, focusing on other product lines instead.
• Analyst sentiment on Tilray remains mixed, with an average "Hold" rating and insider share selling, possibly contributing to the stock's bearish sentiment.
• Market dynamics, including the NASDAQ Composite Index uptrend and the Dow Jones Industrial Average decline, may have further driven the negative pressure on Tilray's stock.

20.04.2026 - TLRY Stock was up 5.3%

• TLRY demonstrated a strong bullish movement despite recent stock pressures.
• Investor optimism in the industry might have been sparked by discussions on cannabis rescheduling and potential regulatory shifts.
• The introduction of new nostalgia-led cocktails by BrewDog, a subsidiary of Tilray, likely positively impacted market sentiment and consumer engagement.
• Positive news and potential catalysts like cannabis legalization and the SAFE banking act may have outweighed analysts' predictions of further declines.

04.04.2026 - TLRY Stock was down 5.1%

• The company faced potential investor concerns with the launch of two new ready-to-drink cocktails by brand 10 Barrel Brewing, a Tilray subsidiary, raising worries about moving away from their core cannabis business.
• Despite surpassing revenue expectations, the stock's decline might be linked to Tilray's larger-than-expected EPS loss, creating uncertainties around the company's profitability and future growth.
• CEO Irwin Simon's positive remarks on the potential reclassification of US cannabis were overshadowed by negative factors like insider selling, stock trading below key moving averages, and overall market sentiment towards the stock.

05.04.2026 - TLRY Stock was down 6.4%

• Tilray's stock price dropped by 4.2% to $5.90, trading below key moving averages, following a wider-than-expected EPS loss of -$0.24 despite beating revenue estimates.
• The broader market also experienced losses, with the NASDAQ Composite Index dropping 0.19% and the Dow Jones Industrial Average falling 1.13%, contributing to Tilray's decline.
• The launch of two new ready-to-drink cocktails by 10 Barrel Brewing, a brand under Tilray, did not seem to positively impact the stock price, as investors may be more focused on the company's financial performance and profitability.
• Analysts' consensus "Hold" rating and lowered price targets suggest caution among investors, reflecting concerns about Tilray's current financial outlook and market conditions.